Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis

This study has been completed.
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc. Identifier:
First received: May 25, 2010
Last updated: June 26, 2012
Last verified: June 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2011
  Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: June 26, 2012